重要内容提示： （网址：http://roadshow.sseinfo.com） 说明会议召开方式：视频和网络文字互动 投资者可于 2023 年 4 月 25 日（星期二）16:00 前登录上证路演中心网站首页 点击"提问预征集"栏目或通过公司邮箱 ir@cansinotech.com 进行提问。公司将 在说明会上对投资者普遍关注的问题进行回答。 康希诺生物股份公司（以下简称"公司"）于 2023 年 3 月 28 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年年度经营成果、 财务状况，公司参与了由上海证券交易所主办的 2022 年度生物制品专场集体业 绩说明会，此次活动将采用视频和网络文字互动的方式举行，投资者可登录上海 证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 证券代码：688185 证券简称：康希诺 公告编号：2023-022 康希诺生物股份公司 关于参加 2022 年度生物制品专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其 ...

Financial Performance - The company reported a net loss for the year 2022, continuing its trend of unprofitability since its IPO[2]. - The company reported a revenue of 1.5 billion in 2022, representing a year-over-year growth of 20%[166]. - The company provided a forward guidance of 1.8 billion in revenue for 2023, expecting a growth rate of 20%[166]. - The company’s net profit attributable to shareholders turned to a loss due to a substantial decline in COVID-19 vaccine sales revenue compared to the same period last year[86]. - The company reported a net cash flow from operating activities of -1,851,545 thousand RMB, a decrease of 190.32% compared to the previous year[67]. - The company’s cash and cash equivalents decreased by 38.62% to 3,464,734 thousand RMB compared to the previous year[71]. - The company’s investment activities resulted in a net cash flow of -1,227,641 thousand RMB, a decrease of 52.05% from the previous year[67]. - The company reported a significant increase in short-term borrowings, rising by 54.42% to 1,529.8 million[85]. - The company’s long-term borrowings increased dramatically by 2,095.02% to 878.0 million, primarily due to new loans for special projects and working capital[85]. - The company’s total sales revenue from major customers reached 520,329 thousand RMB, accounting for 40.49% of total annual sales[64]. Research and Development - The company is focused on the research and development of vaccines and related biotechnologies, aiming to expand its product offerings[34]. - The company has developed a universal mRNA technology that significantly shortens product development time and facilitates rapid industrialization[46]. - The company has established various carrier protein production technologies and coupling techniques for polysaccharide vaccines, enhancing the quality of its multivalent and combination vaccines[45]. - The R&D pipeline includes vaccines for COVID-19, meningitis, Ebola, diphtheria, pertussis, tuberculosis, and shingles, addressing urgent clinical needs[152]. - R&D investment for the mRNA COVID-19 vaccine amounted to CNY 130,415,000, representing 12.61% of total revenue, with a year-over-year increase of 119.11%[114]. - The company has improved existing vaccine products through gene engineering and protein engineering, significantly enhancing antigen yield and simplifying production processes[128]. - The company has developed an inhaled recombinant novel coronavirus vaccine (5-type adenovirus vector) for COVID-19 prevention[92]. - The company has developed a recombinant COVID-19 vaccine (Ad5 vector) and is progressing on a tuberculosis booster vaccine (Ad5Ag85A), leveraging its adenovirus vector technology platform[128]. - The company completed Phase IIb clinical trials for its mRNA COVID-19 vaccine and Phase III clinical trials for the PCV13 vaccine[96]. - The PCV13 vaccine development costs were partially capitalized, with CNY 11,625,000 recognized as capitalized expenses[114]. - The DTcP vaccine's R&D investment was CNY 19,337,000, accounting for 1.87% of total revenue, with a year-over-year increase of 42.12%[114]. - The TB vaccine has completed Phase Ib clinical trials, indicating progress in its development[96]. Market and Strategic Developments - The company plans to invest hundreds of millions in vaccine development, facing risks of potential failures in final development[39]. - The company is actively expanding its marketing network and enhancing its cold chain logistics to improve product penetration[117]. - The company is focusing on importing high-quality vaccines to replace existing products in developed markets, with MCV4 being the first approved product in China using the CRM197 carrier protein[140]. - The company plans to enhance its customer engagement through improved digital platforms, aiming for a 25% increase in customer satisfaction scores[166]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 200 million allocated for potential deals[166]. - The company is involved in various related party transactions as per the annual report[182]. - The company has established agreements to ensure compliance with shareholder obligations, reflecting a commitment to governance[160]. - The company is committed to operational management and strategic development, as highlighted by the roles of its executive team[161]. - The company aims to deepen its R&D platform management and explore global cooperation opportunities to enhance long-term operational and profitability capabilities[142]. - The company is actively engaging in corporate governance improvements, including revisions to internal management systems[177]. Governance and Management - The audit report issued by Deloitte Huayong confirmed the financial statements with a standard unqualified opinion[7]. - The company has established specialized committees, including an audit committee, nomination committee, and compensation and assessment committee, to enhance governance[189]. - The company has a strong leadership team with extensive experience in the biotechnology and pharmaceutical industries[161]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period was 37,487[197]. - The total remuneration for core technical personnel at the end of the reporting period was 24,374[197]. - The company has not reported any changes in shareholding for its non-executive directors during the reporting period[158]. - The company has not faced any penalties from securities regulatory agencies in the past three years[176]. - The company has implemented a plan for share repurchase through centralized bidding, reflecting its commitment to shareholder value[198]. - The company has not identified any risks during the supervisory review conducted by the supervisory board[191]. - The company has a diverse workforce, with 32 employees holding doctoral degrees and 416 holding master's degrees[193]. Operational Challenges and Risks - The company highlighted significant risk factors that could adversely affect its operations, urging investors to be cautious[12]. - The company has not encountered any non-operational fund occupation by controlling shareholders or related parties[29]. - The company’s inventory of COVID-19 vaccines was subject to impairment provisions due to market conditions, leading to increased sales expenses[86]. - The management discussed future plans and strategic developments, emphasizing the importance of risk awareness in investment decisions[8]. - The company has established a drug safety monitoring system to ensure public medication safety[78]. - The company has not disclosed any plans for profit distribution or capital increase through reserves during the reporting period[13]. Charitable Activities - The company made charitable donations totaling 1.18 million, including 1.13 million to foundations and 0.136 million for rural revitalization and pandemic support activities[91].

Financial Performance - For the year ended December 31, 2022, the total revenue was RMB 1,031,041 thousand, a decrease of 76.0% compared to RMB 4,299,702 thousand in 2021[22]. - The operating loss for the year was RMB (1,368,742) thousand, compared to an operating profit of RMB 1,911,612 thousand in the previous year[22]. - The net loss for the year was RMB (964,757) thousand, a significant decline from a net profit of RMB 1,907,086 thousand in 2021[22]. - Basic and diluted loss per share was RMB (3.68) for 2022, compared to earnings of RMB 7.74 per share in 2021[22]. - Gross loss for the year ended December 31, 2022, was approximately RMB 186.6 million, compared to a gross profit of RMB 3,001.9 million in 2021[48]. - Other income increased by 158.3% to approximately RMB 156.9 million, primarily due to increased investment income and government subsidies[49]. - Sales expenses rose to approximately RMB 266.6 million, up from RMB 105.8 million in 2021, driven by increased employee benefits and marketing expenses[50]. - Administrative expenses increased by 20.0% to approximately RMB 278.1 million, attributed to higher depreciation, energy costs, and employee benefits[51]. - R&D expenses decreased by 11.4% to approximately RMB 778.3 million, mainly due to reduced clinical trial costs[52]. - Financial income increased significantly to approximately RMB 184.7 million, up from RMB 25.2 million in 2021, primarily due to foreign exchange gains[54]. - Deferred tax assets recognized during the year resulted in a tax credit of approximately RMB 219.2 million, compared to a tax expense of RMB 29.7 million in 2021[55]. Assets and Liabilities - Non-current assets increased to RMB 3,738,775 thousand in 2022 from RMB 2,584,343 thousand in 2021, reflecting a growth of 44.7%[22]. - Current assets decreased to RMB 7,730,185 thousand in 2022 from RMB 9,289,844 thousand in 2021, a decline of 16.8%[22]. - Total assets were RMB 11,468,960 thousand in 2022, slightly down from RMB 11,874,187 thousand in 2021[22]. - Total equity decreased to RMB 7,245,602 thousand in 2022 from RMB 8,547,884 thousand in 2021, a reduction of 15.2%[22]. - Total liabilities increased to RMB 4,223,358 thousand in 2022 from RMB 3,326,303 thousand in 2021, an increase of 27.0%[22]. Vaccine Development and Innovation - In 2022, the company launched the world's first inhaled COVID-19 vaccine, Convidecia Air®, which received emergency use listing from WHO in May 2022[23]. - The meningococcal conjugate vaccine, Menhycia®, entered nearly 30 provinces in China within four months of its launch, marking it as China's first self-developed conjugate vaccine containing ACYW135 groups[24]. - The company is developing new vaccines, including a bivalent recombinant COVID-19 vaccine and an mRNA vaccine (CS-2034), which have shown good safety and immunogenicity characteristics in clinical trials[23]. - The product pipeline includes 18 vaccines targeting over ten disease areas, with five commercialized products[26]. - The company aims to address unmet medical needs globally with innovative vaccines, including those in preclinical and clinical stages[26]. - The company is actively collaborating with scientific communities and peers to tackle global public health issues related to infectious diseases[23]. - The company is committed to developing high-quality, innovative, and affordable vaccines to meet the growing global demand[26]. Market and Sales Strategy - The company has established a comprehensive marketing and supply system in China, supported by direct sales teams and promotional assistants[24]. - The inhaled COVID-19 vaccine has been delivered to Morocco, contributing significantly to global public health efforts[23]. - The company maintains strong partnerships in both public and private markets, facilitating local production and distribution through technology transfer[24]. - The company is focusing on expanding its commercial operations and has established a business operations center to enhance product commercialization[75]. Corporate Governance - The company has adopted all applicable provisions of the corporate governance code as per the Hong Kong Listing Rules Appendix 14[87]. - The board consists of five executive directors, three non-executive directors, and four independent non-executive directors[89]. - The company has established three committees: Audit Committee, Remuneration and Nomination Committee, each with specific written terms of reference[97]. - The board believes that the current structure of the chairman and CEO roles being held by the same individual is beneficial for the company's business prospects and operational efficiency[91]. - The company has received written annual confirmations of independence from all independent non-executive directors[92]. Risk Management - The company has implemented various risk management procedures and guidelines to identify potential risks affecting its operations[114]. - The board is responsible for evaluating and determining the nature and extent of risks the company is willing to take to achieve strategic objectives[114]. - The company has established a structured approach to risk management and internal control, which is monitored by the Audit Committee[98]. Shareholder Relations - The company encourages shareholder participation in annual general meetings and allows shareholders holding over 10% of shares to request extraordinary meetings[118]. - The company has established multiple communication channels with shareholders, including annual and interim reports, and investor meetings[123]. - The company plans to distribute dividends primarily in cash, with a minimum of 80% of profits allocated to cash dividends during mature stages without significant capital expenditures[127]. Employee and Management - The group employed 2,291 employees as of December 31, 2022, compared to 1,946 employees as of December 31, 2021, indicating an increase of approximately 17.7%[151]. - The total employee benefit expenses amounted to approximately RMB 667.4 million, an increase from RMB 588.8 million as of December 31, 2021, representing a growth of about 13.5%[152]. - The company has adopted a standard code for securities trading by directors and supervisors, with all confirmed compliance during the reporting period[157]. Financial Position and Investments - The company has delayed the full utilization of the remaining balance by one year due to resource allocation for the Ad5-nCoV development and commercialization[167]. - The company plans to utilize the remaining balance of the A-share IPO proceeds by the end of 2024[171]. - The company has maintained compliance with all relevant laws and regulations without any significant violations during the reporting period[182].

Revenue and Profit Performance - Revenue for Q3 2022 was RMB 77,605 thousand, a decrease of 92.42% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2022 was a loss of RMB 486,649 thousand, a decline of 222.65% year-over-year[2] - The significant decline in revenue and profit was primarily due to a substantial decrease in demand for COVID-19 vaccines compared to the previous year[5] - Total operating revenue for the first three quarters of 2022 was 707,395 thousand RMB, a decrease from 3,085,775 thousand RMB in the same period of 2021[17] - Net profit for the first three quarters of 2022 was -488,682 thousand RMB, compared to a net profit of 1,333,896 thousand RMB in the same period of 2021[21] - Basic and diluted earnings per share for the first three quarters of 2022 were -1.92 RMB, compared to 5.39 RMB in the same period of 2021[22] Research and Development - R&D expenses for Q3 2022 totaled RMB 229,531 thousand, an increase of 111.18% compared to the same period last year[3] - R&D expenses accounted for 295.77% of revenue in Q3 2022, an increase of 285.16 percentage points year-over-year[3] - Research and development expenses for the first three quarters of 2022 were 549,066 thousand RMB, a decrease from 655,770 thousand RMB in the same period of 2021[19] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was RMB -1,393,278 thousand, a decrease of 212.07% compared to the same period last year[3] - Cash flow from operating activities for the first three quarters of 2022 was -1,393,278 thousand RMB, compared to 1,243,273 thousand RMB in the previous year[24] - The net increase in cash and cash equivalents for Q3 2022 was -2,490,640[25] - The beginning cash and cash equivalents balance was 5,455,456[25] - The ending cash and cash equivalents balance was 2,964,816[25] Assets and Liabilities - Total assets at the end of the reporting period were RMB 11,539,285 thousand, a decrease of 2.82% from the end of the previous year[3] - The company's cash and cash equivalents decreased to RMB 2,969,159 thousand from RMB 5,645,030 thousand, representing a decline of about 47.4%[13][15] - The total liabilities of the company as of September 30, 2022, were RMB 3,784,224 thousand, up from RMB 3,326,303 thousand, reflecting an increase of about 13.8%[16] - The company's equity attributable to shareholders decreased to RMB 7,216,494 thousand from RMB 7,995,046 thousand, a decline of approximately 9.7%[16] - The company recognized an impairment provision of RMB 526,175.9 thousand for inventory related to COVID-19 vaccines due to a significant decrease in demand compared to 2021[11] Inventory and Receivables - Inventory as of September 30, 2022, was RMB 880,460 thousand, slightly up from RMB 875,621 thousand in the previous year, indicating a marginal increase of 0.1%[13][15] - The company reported accounts receivable of RMB 312,013 thousand, which increased from RMB 157,926 thousand, showing a growth of about 97.5%[13][15] Other Financial Metrics - The weighted average return on equity was -6.53%, a decrease of 12.03 percentage points year-over-year[3] - The company reported a basic and diluted earnings per share of -RMB 1.97 for Q3 2022, a decline of 223.10% compared to the same period last year[3] - The total amount of non-recurring gains and losses for Q3 2022 was RMB 39,165 thousand[4] - Cash inflow from investment activities for the first three quarters of 2022 was 9,360,944 thousand RMB, significantly higher than 3,968,365 thousand RMB in the same period of 2021[24] - Cash outflow from investment activities for the first three quarters of 2022 was 11,284,530 thousand RMB, compared to 6,201,509 thousand RMB in the previous year[24] - Net cash flow from financing activities for the first three quarters of 2022 was 628,605 thousand RMB, down from 1,397,063 thousand RMB in the same period of 2021[24] - The company reported a tax expense of -158,171 thousand RMB for the first three quarters of 2022, compared to -43,506 thousand RMB in the previous year[19]

Financial Performance - For the nine months ended September 30, 2022, the company's operating revenue attributable to shareholders was RMB 77,605 thousand, a decrease of 92.42% compared to the same period last year[3]. - The net profit attributable to shareholders for the same period was a loss of RMB 486,649 thousand, representing a decline of 222.65% year-on-year[3]. - Total revenue for the first three quarters of 2022 was RMB 707,395 thousand, a significant decrease from RMB 3,085,775 thousand in the same period of 2021, representing a decline of approximately 77%[19]. - Operating profit for the first three quarters of 2022 was a loss of RMB 645,593 thousand, compared to a profit of RMB 1,295,251 thousand in the same period of 2021[22]. - Net profit attributable to shareholders for the first three quarters of 2022 was a loss of RMB 488,682 thousand, while in 2021, it was a profit of RMB 1,333,896 thousand, indicating a substantial decline[24]. - The company reported a total comprehensive loss of RMB 488,626 thousand for the first three quarters of 2022, contrasting with a total comprehensive income of RMB 1,333,896 thousand in the same period of 2021[27]. Expenses and R&D - Research and development expenses totaled RMB 229,531 thousand, an increase of 111.18% compared to the same period last year, with R&D expenses accounting for 295.77% of operating revenue[3]. - The company paid RMB 489,173 thousand in cash to employees in the first three quarters of 2022, an increase from RMB 255,832 thousand in 2021[29]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 11,539,285 thousand, a decrease of 2.82% from the end of the previous year[4]. - The equity attributable to shareholders decreased by 9.74% to RMB 7,216,494 thousand compared to the previous year-end[4]. - Total liabilities as of September 30, 2022, amounted to RMB 3,784,224 thousand, an increase from RMB 3,326,303 thousand as of December 31, 2021[17]. - Current liabilities totaled RMB 2,770,161 thousand as of September 30, 2022, down from RMB 2,861,417 thousand at the end of 2021, reflecting a decrease of approximately 3.2%[15]. - Non-current liabilities increased to RMB 1,014,063 thousand as of September 30, 2022, compared to RMB 464,886 thousand at the end of 2021[17]. Cash Flow - The net cash flow from operating activities for the nine months was a loss of RMB 525,814 thousand, a decline of 240.05% year-on-year[3]. - Operating cash flow for the first three quarters of 2022 was negative at RMB (1,393,278) thousand, compared to a positive RMB 1,243,273 thousand in the same period of 2021[29]. - Cash inflow from investment activities increased significantly to RMB 9,360,944 thousand in 2022, up from RMB 3,968,365 thousand in 2021[30]. - Net cash flow from financing activities in 2022 was RMB 628,605 thousand, a decrease from RMB 1,397,063 thousand in 2021[30]. - The total cash and cash equivalents at the end of Q3 2022 were RMB 2,964,816 thousand, down from RMB 4,864,798 thousand at the end of Q3 2021[31]. - The company reported a significant increase in cash received from investment recoveries, totaling RMB 8,836,912 thousand in 2022 compared to RMB 3,936,000 thousand in 2021[30]. - The net cash flow from investment activities was negative at RMB (1,923,586) thousand in 2022, compared to RMB (2,233,144) thousand in 2021[30]. Market Conditions - The company attributed the significant decline in revenue and profit primarily to a sharp decrease in demand for COVID-19 vaccines and adjustments in product pricing[6]. - The company has identified a competitive market environment for COVID-19 vaccines, with a notable decrease in demand since 2021, leading to potential challenges in future sales[10]. - The company has conducted impairment tests on COVID-19 vaccine-related assets due to signs of impairment, reflecting a proactive approach to asset management in a changing market[10]. Shareholder Information - The top shareholder, HKSCC Nominees Limited, holds 39.63% of the total shares, with a total of 98,062,297 shares[9].

Financial Performance - Revenue for the first half of 2022 was RMB 629.79 million, a decrease of 69.45% compared to RMB 2,061.46 million in the same period of 2021[7] - Operating loss for the first half of 2022 was RMB 164.80 million, a decline of 120.54% from a profit of RMB 802.33 million in the first half of 2021[7] - Total comprehensive income for the period was RMB 16.04 million, down 98.29% from RMB 937.13 million in the previous year[7] - Basic and diluted earnings per share decreased to RMB 0.0495, a drop of 98.69% from RMB 3.7872 in the same period of 2021[7] - Gross profit for the same period was approximately RMB 316.2 million, down 78.0% from RMB 1,436.2 million in the prior year, primarily due to price changes in vaccine products and increased inventory write-downs[46] - The net loss before tax was RMB 41.56 million, compared to a profit of RMB 836.83 million in the same period of 2021[113] - The company reported a total profit of RMB 12.24 million for the first half of 2022, a significant decrease from the previous year's profit[118] Assets and Liabilities - Total assets slightly increased by 0.97% to RMB 11,989.10 million compared to RMB 11,874.19 million at the end of 2021[9] - Non-current assets increased by 15.56% to RMB 2,986.51 million from RMB 2,584.34 million as of December 31, 2021[9] - Total liabilities rose by 12.20% to RMB 3,732.21 million from RMB 3,326.30 million as of December 31, 2021[9] - Cash and cash equivalents decreased by 19.7% from approximately RMB 4,490.9 million as of December 31, 2021, to approximately RMB 3,608.1 million as of June 30, 2022[67] - Inventory rose significantly from approximately RMB 875.6 million as of December 31, 2021, to approximately RMB 1,188.5 million as of June 30, 2022, primarily due to increases in finished goods and work-in-progress, partially offset by inventory write-downs of approximately RMB 98.2 million[60] - Accounts receivable increased significantly from approximately RMB 157.9 million as of December 31, 2021, to approximately RMB 315.8 million as of June 30, 2022, mainly due to an increase in domestic accounts receivable with extended collection periods compared to last year[61] Research and Development - The company is developing 17 vaccine candidates across 12 disease areas, with several products already commercialized in China[11] - The company aims to replace existing mainstream vaccines in China with higher quality, innovative vaccines[11] - The mRNA COVID-19 vaccine clinical trial was approved in China in April 2022 and is currently in Phase II trials[16] - The company is establishing an mRNA technology platform in Shanghai to develop innovative preventive vaccine products with independent intellectual property rights[37] - The company is developing the improved PCV13i vaccine, with Phase III clinical trials expected to complete in the second half of 2022[27] - The innovative PBPV vaccine targets over 90 serotypes of pneumonia, with Phase I clinical trials completed and Phase Ib trials expected to start by the end of 2022[30] Marketing and Commercialization - The company has received emergency use authorizations for its vaccine products in multiple countries since February 2021[11] - Kweisha received approval for sequential booster immunization in China in February 2022[16] - The first batch of Manhaixin products received approval from the National Medical Products Administration in June 2022, marking its commercialization in China[22] - Manhaixin has achieved market access in nearly 20 provinces in China as of the report date[22] - The company has established a complete commercial operation center to support the promotion and marketing strategies for its products[22] - The company terminated its promotion agreement with Pfizer for Manhaixin in June 2022, allowing for independent marketing efforts[22] Financial Position and Investments - The company plans to invest approximately RMB 2,244.7 million in the CanSino Innovative Vaccine Industrial Park project to enhance manufacturing capacity[70] - As of June 30, 2022, the company's capital commitments amounted to approximately RMB 262.7 million, a decrease of 15.7% from RMB 311.7 million as of December 31, 2021[72] - The company has repurchased 500,000 A-shares at a total cost of RMB 113.88 million, including transaction costs[105] - The company anticipates that the remaining balance of the A-share IPO proceeds will be fully utilized by the end of 2024[101] Corporate Governance - The board of directors has maintained compliance with corporate governance codes, although the roles of chairman and CEO are held by the same individual[79] - The audit committee reviewed the interim financial results for the six months ended June 30, 2022, and found them to comply with applicable accounting standards and regulations[84] - The company did not recommend the payment of an interim dividend for the reporting period[86] Shareholder Information - As of June 30, 2022, the total number of H shares held by Dr. Mao is 34,598,400, representing approximately 13.98% of the company's total equity and 26.08% of the H share category[88] - The total number of A shares held by Dr. Mao is 42,579,625, representing approximately 17.21% of the company's total equity and 37.10% of the A share category[88] - The Capital Group Companies, Inc. holds 32,805,889 H shares, accounting for approximately 13.26% of the company's total equity and 24.73% of the H share category[93] - The company has a controlled entity interest from BlackRock, Inc. with 6,893,089 H shares, accounting for approximately 2.79% of the company's total equity and 5.20% of the H share category[95]

Financial Performance - Cansino reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year decrease of 30%[1]. - The company’s net loss for the period was RMB 500 million, compared to a net profit of RMB 200 million in the same period last year[1]. - The company's revenue for the first half of 2022 was CNY 629.79 million, a decrease of 69.45% compared to CNY 2,061.46 million in the same period last year[14]. - The net profit attributable to shareholders was CNY 12.24 million, down 98.69% from CNY 937.13 million year-on-year[14]. - The net cash flow from operating activities was negative CNY 1,213.52 million, a decline of 257.90% compared to CNY 768.52 million in the previous year[14]. - The company has set a revenue guidance of RMB 2.5 billion for the full year 2022, reflecting a cautious outlook due to market conditions[1]. - The company achieved revenue of RMB 629,790 thousand, a decrease of 69.45% compared to the same period last year[56]. - Net profit attributable to shareholders was RMB 12,238 thousand, down 98.69% year-on-year[56]. - The total assets increased by 0.97% to RMB 11,989,097 thousand, while net assets attributable to shareholders decreased by 3.69% to RMB 7,700,245 thousand[56]. Research and Development - Cansino is investing RMB 300 million in R&D for new vaccine technologies, aiming to launch two new products by 2024[1]. - The R&D expenditure accounted for 51.80% of the revenue, an increase of 24.31 percentage points compared to 27.49% in the previous year[15]. - The company has developed a pipeline of 17 innovative vaccines targeting various diseases, including COVID-19 and Ebola, with several products already receiving emergency use authorization[19]. - The company has established five major technology platforms for vaccine research, showcasing its strong R&D capabilities[26]. - The company reported a total R&D investment of CNY 326,226 thousand, a decrease of 42.44% compared to the previous year, with a significant drop in capitalized R&D investment by 85.37%[32]. - The company is advancing multiple vaccine projects, including the Ad5-nCoV COVID-19 vaccine with a total investment of CNY 1,130,000 thousand, which has received emergency use authorization in several countries[33]. - The company has established a comprehensive quality management system that meets international standards for vaccine production, ensuring the safety and quality of its products[37]. Market Expansion and Strategy - User data indicates that Cansino's vaccine distribution reached 100 million doses globally, with a significant portion in emerging markets[1]. - The company plans to expand its market presence in Southeast Asia and Latin America, targeting a 20% increase in market share by the end of 2023[1]. - Cansino is exploring strategic partnerships for potential mergers and acquisitions to enhance its product pipeline and market reach[1]. - The company has deepened international cooperation, including a partnership with Malaysia's National Institute of Biotechnology and Solution Biologics for vaccine development and commercialization[50]. Financial Position and Cash Flow - Cansino's cash reserves stand at RMB 1 billion, providing a buffer for ongoing operations and strategic initiatives[1]. - The company reported a non-recurring gain of RMB 33,665 thousand from government subsidies closely related to its normal business operations[17]. - The total amount of financial assets measured at fair value reached 3,293,370 thousand RMB, up from 1,907,985 thousand RMB[63]. - The company has ongoing property leases with various entities, with total lease amounts including RMB 202,967,000 and RMB 11,368,000 for different properties[112]. - The company has utilized CNY 250 million for supplementary working capital, achieving 100% of the planned investment[117]. Risks and Challenges - The company has identified key risk factors, including regulatory changes and competition, which may impact future performance[1]. - The global vaccination rate is expected to slow down, leading to increased market competition and potential price declines for COVID-19 vaccines[51]. - The company faces significant risks, including potential performance declines due to R&D project setbacks and increased competition from larger firms[52]. Environmental and Governance Practices - The company has established an environmental management system and has not faced any administrative penalties for environmental violations as of the reporting period[70]. - The company is committed to low-carbon production and has taken measures such as equipment upgrades and increased use of renewable energy to reduce carbon emissions[73]. - The company has made commitments regarding share lock-up periods, with major shareholders agreeing not to transfer or reduce their holdings for 36 months post-IPO, ensuring stability in the share structure[75]. Shareholder and Equity Information - The company has established a plan to stabilize A-share prices for three years post-IPO, which includes potential stock buybacks[88]. - The company will adhere to the specific implementation plan for stabilizing stock prices if certain conditions are met within three years of the IPO[89]. - The company has committed to not reducing its holdings of A-shares for three complete accounting years if it has not achieved profitability post-IPO[85]. - The company has outlined specific commitments related to share incentives, ensuring that the vesting of restricted stock awards aligns with performance metrics over a maximum period of 48 months[76]. Compliance and Accounting Policies - The financial statements are prepared based on the accrual basis of accounting, with historical cost as the measurement basis for most assets and liabilities[163]. - The company’s financial statements for the first half of 2022 comply with the requirements of the accounting standards and reflect the financial position as of June 30, 2022[166]. - The group recognizes foreign exchange differences arising from foreign currency transactions directly in the current profit and loss, except for those related to capitalized assets[175].

Financial Performance - Total revenue for Q1 2022 was RMB 499,355 thousand, representing a year-on-year increase of 6.98%[2] - Net profit attributable to shareholders was RMB 121,413 thousand, with basic and diluted earnings per share both at RMB 0.49[2] - Operating profit for Q1 2022 was RMB 121,874 thousand, a significant recovery from a loss of RMB 16,190 thousand in Q1 2021[16] - Net profit for Q1 2022 amounted to RMB 114,295 thousand, compared to a loss of RMB 15,752 thousand in Q1 2021[16] - The net profit attributable to shareholders of the parent company was 121,413,000, compared to a net loss of 14,114,000 in the previous period[17] - The total comprehensive income attributable to shareholders of the parent company was 121,413,000, while the comprehensive income attributable to minority shareholders was -7,118,000, compared to -1,638,000 in the previous period[17] - The basic and diluted earnings per share were both 0.49 yuan, compared to a loss of 0.06 yuan per share in the previous period[17] Research and Development - R&D investment totaled RMB 159,416 thousand, a decrease of 40.91% compared to the previous year[2] - R&D expenses accounted for 31.92% of total revenue, a decrease of 25.88 percentage points year-on-year[3] - Research and development expenses for Q1 2022 were RMB 157,155 thousand, a decrease of 41.7% from RMB 269,788 thousand in Q1 2021[16] Cash Flow and Liquidity - The net cash flow from operating activities was negative at RMB -598,148 thousand, primarily due to longer collection cycles and increased cash payments for raw materials and employee salaries[2][5] - Cash inflows from operating activities totaled 230,369,000, down from 525,180,000 in the previous period[19] - Cash outflows from operating activities amounted to 828,517,000, compared to 537,596,000 in the previous period[19] - The net cash flow from investment activities was -894,010,000, compared to 8,094,000 in the previous period[20] - The net increase in cash and cash equivalents was -1,481,585,000, compared to an increase of 232,336,000 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were RMB 11,933,983 thousand, a slight increase of 0.50% from the end of the previous year[3] - Non-current assets totaled RMB 2,811,478 thousand, an increase of 8.8% from RMB 2,584,343 thousand year-over-year[15] - Current liabilities decreased to RMB 2,774,427 thousand from RMB 2,861,417 thousand, reflecting a reduction of 3.0%[15] - Long-term borrowings increased to RMB 155,000 thousand from RMB 40,000 thousand, indicating a rise of 287.5%[15] - Total equity attributable to shareholders rose to RMB 8,034,486 thousand, compared to RMB 7,995,046 thousand in the previous year[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,318[7] - Major shareholders included HKSCC NOMINEES LIMITED with a 39.63% stake and Xuefeng Yu with a 7.22% stake[7] - The company has approved a share repurchase plan with a total amount not less than RMB 150 million and not exceeding RMB 300 million, with a repurchase price cap of RMB 446.78 per share[12] - The company has repurchased a total of 325,000 A shares through the Shanghai Stock Exchange as of March 31, 2022[12] Product Development and Market Outlook - The company’s new COVID-19 vaccine, Kweisha®, received domestic approval for sequential booster immunization in February 2022 and is undergoing WHO GMP certification[10] - The global vaccination rate is expected to slow down, with increased competition in the COVID-19 vaccine market leading to potential price declines[11] - The company is in the process of including Kweisha® in the WHO's Emergency Use Listing (EUL) following its approval[10] Other Financial Metrics - Non-recurring gains and losses totaled RMB 39,199 thousand, including government subsidies of RMB 22,264 thousand and fair value changes of financial assets of RMB 21,010 thousand[4] - The weighted average return on equity was 1.51%[2] - The company's cash and cash equivalents decreased to RMB 4,290,250, down from RMB 5,645,030 in the previous year, representing a decline of approximately 24%[13] - The total current assets amounted to RMB 9,122,505, a slight decrease from RMB 9,289,844 in the previous year, indicating a reduction of about 1.8%[13] - The company's inventory increased to RMB 1,121,661, up from RMB 875,621, reflecting a growth of approximately 28%[13] - The accounts receivable rose significantly to RMB 350,532, compared to RMB 157,926 in the previous year, marking an increase of about 122%[13]

Financial Performance - The company's operating revenue for the first quarter was RMB 499,355,000, representing a year-on-year increase of 6.98%[4] - Net profit attributable to shareholders was RMB 121,413,000, with a basic and diluted earnings per share of RMB 0.49[4] - Total revenue for Q1 2022 reached RMB 499,355 thousand, an increase of 6.3% compared to RMB 466,758 thousand in Q1 2021[22] - Operating profit for Q1 2022 was RMB 121,874 thousand, a significant recovery from a loss of RMB 16,190 thousand in Q1 2021[23] - Net profit for Q1 2022 was RMB 114,295 thousand, compared to a net loss of RMB 15,752 thousand in Q1 2021[23] - Basic earnings per share for Q1 2022 was RMB 0.49, recovering from a loss of RMB 0.06 per share in Q1 2021[24] Research and Development - Research and development expenses totaled RMB 159,416,000, a decrease of 40.91% compared to the previous year, accounting for 31.92% of operating revenue[4][7] - Research and development expenses for Q1 2022 were RMB 157,155 thousand, down from RMB 269,788 thousand in Q1 2021, a decrease of 41.7%[22] Assets and Liabilities - The total assets at the end of the reporting period were RMB 11,933,983,000, reflecting a 0.50% increase from the previous year[5] - The total liabilities as of March 31, 2022, amounted to RMB 3,353,777 thousand, slightly up from RMB 3,326,303 thousand as of December 31, 2021[20] - Total equity increased to RMB 8,580,206 thousand as of March 31, 2022, compared to RMB 8,547,884 thousand at the end of 2021[20] - Long-term borrowings rose significantly to RMB 155,000 thousand in Q1 2022 from RMB 40,000 thousand in Q4 2021, an increase of 287.5%[20] Cash Flow - The net cash flow from operating activities was negative at RMB (598,148,000), indicating a decrease in cash inflow compared to the same period last year[4][7] - Cash inflow from operating activities totaled 230,369,000, a decrease from 525,180,000 in the previous year[26] - Cash outflow from operating activities increased to 828,517,000, compared to 537,596,000 in the prior year[26] - Cash inflow from investment activities was 2,135,294,000, up from 304,765,000 year-over-year[27] - Net cash flow from investment activities was (894,010,000), compared to 8,094,000 in the prior year[27] - Cash inflow from financing activities was 517,416,000, compared to 251,535,000 in the previous year[27] - Net cash flow from financing activities was 22,723,000, down from 228,284,000 year-over-year[27] - The net increase in cash and cash equivalents was (1,481,585,000), compared to an increase of 232,336,000 in the prior year[28] - The ending balance of cash and cash equivalents was 3,973,871,000, down from 4,678,365,000 in the previous year[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,318[8] - The top shareholder, HKSCC Nominees Limited, held 39.63% of the shares[9] Strategic Initiatives - The company plans to continue its focus on the commercialization of its products, which has positively impacted net profit attributable to shareholders[7] - The company has engaged in strategic partnerships and investments, including the involvement of several venture capital firms as significant shareholders, indicating a collaborative approach to market expansion and innovation[11] Market Context - The global vaccination rate is expected to slow down, with increased competition in the COVID-19 vaccine market, which may lead to a decrease in supply prices and heightened demands for product safety and efficacy[14] - The company’s ongoing development of a new COVID-19 vaccine has received approval for sequential booster immunization in China as of February 2022, and it is currently undergoing the process to include the vaccine in the WHO's Emergency Use Listing[13]

Financial Performance - Total revenue for 2021 reached RMB 4,299,702 thousand, a significant increase from RMB 18,544 thousand in 2020[8] - Operating profit for 2021 was RMB 1,911,612 thousand, compared to an operating loss of RMB 400,859 thousand in 2020[8] - The net profit for the year was RMB 1,907,086 thousand, a turnaround from a loss of RMB 396,638 thousand in 2020[8] - Basic and diluted earnings per share for 2021 were RMB 7.74, recovering from a loss of RMB 1.72 per share in 2020[8] - Gross profit for the year ended December 31, 2021, was approximately RMB 3,003.2 million, compared to RMB 4.7 million in 2020, marking a turnaround to profitability[39] - Research and development expenses increased by 105.1% to approximately RMB 878.7 million for the year ended December 31, 2021, primarily due to increased clinical trial and testing costs[43] - Selling expenses rose from approximately RMB 16.6 million in 2020 to approximately RMB 105.8 million in 2021, attributed to increased employee benefits and marketing expenses[41] - Administrative expenses increased from approximately RMB 82.9 million in 2020 to approximately RMB 231.8 million in 2021, driven by rapid business expansion[42] - Financial income net increased significantly from approximately RMB 4.2 million in 2020 to approximately RMB 25.2 million in 2021, mainly due to higher interest income[45] Assets and Liabilities - Total assets increased to RMB 11,874,187 thousand in 2021, up from RMB 6,748,073 thousand in 2020[8] - Total equity rose to RMB 8,547,884 thousand in 2021, compared to RMB 6,070,854 thousand in 2020[8] - Non-current assets reached RMB 2,584,343 thousand, a significant increase from RMB 1,327,430 thousand in 2020[8] - Current assets grew to RMB 9,289,844 thousand, up from RMB 5,420,643 thousand in 2020[8] - Total liabilities were RMB 3,326,303 thousand in 2021, compared to RMB 677,219 thousand in 2020[8] - Other payables and accrued expenses increased by 128.4% from approximately RMB 299.7 million as of December 31, 2020, to approximately RMB 684.5 million as of December 31, 2021, primarily due to increases in payables to suppliers, wages and benefits, and clinical trial costs[52] Vaccine Development and Clinical Trials - The clinical trial results for the COVID-19 vaccine, Convidecia, were published in The Lancet, confirming its strong protective efficacy[9] - Convidecia has received emergency use authorization in multiple countries, including Mexico, Pakistan, and Hungary[11] - The MCV2 and MCV4 vaccines received new drug application approvals from the National Medical Products Administration in China[10] - The company is developing 17 vaccine candidates across 12 disease areas, with 8 in clinical trial stages[11] - The PCV13i vaccine's Phase III clinical trial enrollment began in April 2021[14] - The Ad5-nCoV vaccine has achieved significant progress, with interim analysis in February 2021 showing it met primary safety and efficacy standards in a Phase III clinical trial[17] - The company has developed an inhaled version of Ad5-nCoV, which shows unique advantages in safety, efficacy, and convenience, with ongoing clinical trials[18] - MCV2 has been commercialized in China, entering nearly 20 provinces, and has shown better safety and immunogenicity compared to existing products[19] - MCV4 is positioned as a potential first-in-class vaccine in China for preventing meningococcal meningitis, with a commercial launch initiated following its approval[20] - The company is developing a modified PCV13 vaccine (PCV13i) aimed at competing with world-class products for children under 2 years old, with Phase III trials ongoing[23] Market Expansion and Future Plans - The company plans to continue expanding its market presence and invest in new product development and technologies[6] - The company plans to continue commercializing its vaccines and expand its sales and marketing team to enhance product sales[36] - The group plans to invest approximately RMB 2,244.7 million in the innovative vaccine industrial park project[57] - The company is focused on expanding its commercial operations and product commercialization strategies[67] - The company is committed to developing new products and technologies to strengthen its competitive position in the market[66] Corporate Governance and Management - The company has established a remuneration and assessment committee to review the remuneration policies for all directors and senior management based on performance and market practices[146] - The board consists of five executive directors, three non-executive directors, and four independent non-executive directors, ensuring a diverse and experienced leadership team[83] - The company has adopted a corporate governance code and believes it has complied with all applicable code provisions during the reporting period, except for the separation of the roles of Chairman and CEO[150] - The board is responsible for leading and monitoring the company, ensuring good internal controls and risk management systems are in place[90] - The company has established appropriate insurance for directors and senior officers to cover legal actions taken due to company affairs[91] Shareholder Communication and Dividends - The board of directors proposed a final cash dividend of RMB 8 per ten shares for the year ended December 31, 2021, subject to shareholder approval[121] - The total amount of the proposed dividend is RMB 197,699,919.20 (including tax), based on the number of shares eligible for dividend distribution as of March 25, 2022[121] - The company has established a shareholder communication policy to ensure that shareholder opinions and concerns are properly addressed[115] - The company plans to prioritize cash dividends, with a minimum of 80% of profits distributed as cash dividends during mature stages without significant capital expenditure[118] Risks and Challenges - The company has faced significant competition in the vaccine market, which may impact its financial outlook[125] - The company may require significant additional financing to continue operations, and failure to secure necessary capital could delay or terminate product development efforts[125] - The company is exposed to risks related to regulatory approvals for its vaccine candidates, which may affect commercialization efforts[127] - The ongoing pandemic may continue to impact the company's operations, including clinical trials and product launches[127] Research and Development - The company has established an international-level R&D technology platform, leading to the development of multiple new vaccines[65] - The company is actively pursuing international registration for its vaccine products and advancing multiple international cooperation projects[76] - The company is developing a novel non-serotype pneumococcal vaccine (PBPV) that targets over 90 serotypes, with over 98% of strains in Nanjing belonging to PspA family 1 or 2, potentially offering broader coverage than existing PPV23 and PCV13 products[24] Financial Position and Capital Management - The company is in a net cash position as of December 31, 2021, making the debt-to-equity ratio not applicable[62] - The total actual use of funds for the A-share IPO was RMB 1,345.7 million, with a remaining balance of RMB 2,185.4 million as of December 31, 2021[165] - The company has allocated RMB 420.0 million for the development of advanced technologies and related acquisitions, expected to be fully utilized by the end of 2023[163]